Hepatocellular cancer

Medivir's Phase Ib/IIa study completed

Medivir's Phase Ib/IIa study successfully completed

Medivir has now completed the phase Ib/IIa study evaluating fostrox in combination with Lenvima as a second- or third-line treatment...

Intervju
Medivir optimizes study design after meeting with FDA

Medivir optimizes study design after meeting with FDA

Medivir has had another meeting with the FDA...

Intervju

Medivir continues to accelerate development with fostrox

Medivir's recently published annual report for 2023 focuses primarily on...

Intervju
Pia Baumann, CMO Medivir

Medivir's CMO: "Our new clinical data is very encouraging"

Medivir presents the first clinical results with fostrox...

Intervju
Medivir announces improved durable clinical benefit with fostrox

Medivir sees lasting clinical benefit with fostrox

Medivir, whose ongoing rights issue ends today, the 21st...
Medivir clears key hurdles ahead of phase IIb

Medivir checks off two steps ahead of Phase IIb

Medivir, which is currently in the process of issuing shares, has made progress in a short time...
Medivir aims for accelerated FDA approval through issuance

Medivir aims for accelerated FDA approval through issuance

Hepatocellular carcinoma is the most common form of primary...
Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"

Medivir's CEO comments on the ongoing rights issue

Medivir is currently conducting a rights issue of up...

Intervju

Interview: Magnus Hansson about NeuroVive's positive cancer data

Last week, NeuroVive Pharmaceutical was able to announce to the market that...

New preclinical data from NeuroVive: "Unexpectedly powerful anti-cancer effects"

NeuroVive was today able to announce new positive cancer data from...